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ABSTRACT
KRAS is a frequently mutated oncogene in lung cancer and among the most 
refractory to EGFR targeted therapy. Recently, preclinical evidence in pancreatic 
cancer has demonstrated that mutant KRAS can be regulated by EGFR. However, the 
distinct correlation between the EGFR/HER family members and mutant KRAS has not 
been investigated. Here, we show that non-small cell lung cancer cell lines harboring 
differing isoforms of mutant KRAS, can be broadly divided into EGFR/HER dependent 
and EGFR/HER independent groups. Combined therapeutic targeting of EGFR, HER2 
and HER3 in isoforms regulated by extracellular growth signals promotes in vitro and 
in vivo efficacy. We also provide evidence that depletion of EGFR via RNA interference 
specifically abolishes the EGFR/KRAS interaction in the dependent subset. Taken 
together, these findings suggest that upstream inhibition of the EGFR/HER receptors 
may be effective in treating a subset of KRAS mutant lung cancers.
INTRODUCTION
The identification and characterization of genetic 
abnormalities attributed to the development of lung cancer 
has enabled advancement in understanding the biology and 
pathophysiology of the disease. The most common genetic 
alterations observed in non-small cell lung cancer (NSCLC) 
occur in the epidermal growth factor receptor (EGFR) 
gene, a member of the HER family (Human Epidermal 
Growth Factor Receptor) of transmembrane receptor 
tyrosine kinases (RTKs), and in KRAS - a member of the 
Ras family of small GTPases, which also includes HRAS 
and NRAS [1]. Oncogenic KRAS missense mutations 
are found in approximately 10–30% of lung carcinomas 
where they typically cluster around codon 12, codon 13 
or more rarely codon 61 [2–3]. These substitutions have 
been described to deregulate RAS signaling by decreasing 
GTP-ase activity, and hence constitutively activating down-
stream signaling molecules independent of ligand- mediated 
EGFR activation [4]. Current knowledge suggests that this 
downstream activation renders upstream EGFR inhibition 
irrelevant in the context of possible therapeutic intervention. 
Moreover these cancers are consistently wild-type EGFR 
which on itself precludes significant therapeutic efficacy 
from single EGFR inhibition.
There is currently no established therapy 
available for KRAS mutant cancers [5]. Various efforts 
to specifically target KRAS with farnesyl transferase 
inhibitors (FTIs), which block RAS membrane attachment 
and RAS signaling, have failed to show a significant 
enzyme inhibitory activity needed for clinical activity, 
which may explain the limited therapeutic effect of FTIs 
in phase II lung cancer trials [6]. Other strategies to 
specifically target the activity of oncogenic RAS have also 
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provided no significant therapeutic benefit, although this 
still remains an active area of research [7–8]. Currently, 
downstream targeting of the RAS pathway (MEK 
inhibition) is under clinical investigation [9–11].
While multiple reports have described the 
constitutively active oncogenic KRAS to be independent 
of EGFR [12–13], recent evidence in pancreatic cancer 
has indicated that signaling by mutant KRAS may be 
dependent on upstream activation of EGFR [14–15]. 
Moreover, Young et al, recently proposed that oncogenic 
KRAS may also be regulated by upstream activation of 
several receptor tyrosine kinases (RTKs) [16]. Besides 
EGFR the distinct role of other HER receptor members, 
such as HER2 and HER3, in modulating mutant KRAS-
driven tumorigenesis is not known. We therefore examined 
the collective contribution of EGFR, HER2 and HER3 in 
the molecular mechanism underlying the pathogenesis 
of KRAS mutant lung cancer. We present divergent 
cellular mechanisms associated with RTK-dependent 
and RTK-independent cell lines and provide in vitro and 
in vivo evidence demonstrating the anti-tumor efficacy 
of targeting EGFR/HER in the RTK-dependent subset. 
Our model suggests that in a group of mutant KRAS 
lung cancers, EGFR is not the major upstream signaling 
activator, but that this role is also played by HER2 and 
HER3. Multi-targeting the HER receptors may thus have 
positive implications for the treatment of tumors that 
harbor these specific mutant KRAS isoforms.
RESULTS
Silencing oncogenic KRAS in KRAS-dependent 
NSCLC cells
Four human NSCLC cell lines with differing 
KRAS and EGFR mutational status, H292 (KRASwt; 
EGFRwt), H358 (KRASG12C; EGFRwt), H1650 (KRASwt; 
EGFRΔE746-A750) and H1975 (KRASwt; EGFRL858R + T790M), 
were assessed for RAS-GTP activity by a Raf ‘pull down 
assay’ using the RAS-binding domain of Raf-1. H358 cells 
harboring oncogenic KRAS displayed elevated levels of 
active KRAS-GTP (isoform specific) and pan-RAS-GTP 
when compared to the other NSCLC cell lines (Fig. 1a). 
Interestingly, although H1650 cells express lower levels 
of total KRAS compared to the other cell lines, the 
normalized ratio of active KRAS-GTP to total KRAS was 
relatively high- a calculated ratio of 2.42 compared to a 
ratio of 2.62 for H358 cells (Fig. 1a). However, the overall 
KRAS-GTP signal observed in H1650 cells remains very 
low compared to H358 cells.
To also examine the respective roles of wild-type and 
mutant KRAS in the growth of H358 cells, siRNAs specific 
to wild-type KRAS and mutant KRAS G12C isoforms [17] 
were utilized in functional experiments. As shown in 
Fig. 1b, H358 cells exposed to mutant-specific KRAS 
siRNA displayed a ~40% reduction in cellular growth after 
72 hrs (MTS assay), while a ~15% reduction was observed 
after wild-type KRAS siRNA treatment (Fig. 1b). Similar 
observations were seen with H23 (KRASG12C; EGFRwt) 
cells (Fig. S1a). H1650 cells, carrying an activating EGFR 
mutation, demonstrated a ~15% significant reduction in cell 
growth after respective siRNA treatment with either wild-
type or mutant KRAS (Fig. 1b). This observation could be 
as a result of the relatively enhanced levels of active KRAS 
seen in H1650 cells (Fig. 1a); possibly related to the absence 
of the PTEN phosphatase in this cell line [18]. No significant 
inhibitory effects were observed on the cellular growth 
of either H1975 cells carrying the EGFRT790M resistance 
mutation or H292 control cells after similar treatments 
(Fig. 1b).
To determine the molecular changes associated 
with the decrease in cellular growth, we examined 
KRAS protein expression and effector signaling. A 
siRNA-mediated depletion of the wild-type KRAS 
isoform reduced the expression of KRAS in the 
control cell line as well as in the two EGFR mutant 
cell lines (Fig. 1c). In contrast, while knockdown of 
wild-type KRAS did not significantly reduce KRAS 
protein expression in H358 cells, mutant-specific 
knockdown potently and specifically reduced KRAS 
protein expression (Fig. 1c). Depletion of oncogenic 
KRAS impaired AKT phosphorylation in H358 cells, 
but resulted in a more robust induction of STAT3 
phosphorylation at Tyr 705, compared to wild-type 
KRAS knockdown (Fig. 1c), indicating a feedback 
activation of STAT3. Similar results were also observed 
with the H23 cells harboring the same KRAS mutation 
(Fig. S1b). Our results show a modest reduction in 
phosphorylated STAT3 levels at Tyr 705 in H292 
control cells with mutant KRAS G12C knockdown 
(Fig. 1c). The reduction of STAT3 could be the result of 
an miRNA effect [19], since sequence alignment of the 
mutant specific KRAS siRNA and EGFR reveals partial 
homologies, e.g. within the 3′ untranslated region of 
EGFR beginning at position 2098 (data not shown). In 
H1650 mutant EGFR cells, mutant KRAS knockdown 
also reduced KRAS protein levels but without a 
significant effect on the downstream signal transduction 
pathways (Fig. 1c). Again, this could be related to the 
relatively high levels of active KRAS seen in this cell 
line (Fig. 1a). The absence of effects on the downstream 
pathways was also observed in the H1975 cells.
To examine the effect of wild-type or mutant specific 
KRAS siRNA on the survival of the NSCLC cell lines, 
Hoechst 33342/Propidum Iodide (PI) double chromatin 
staining was performed to detect DNA condensation in cell 
cultures 72 hrs post-transfection. The number of apoptotic 
cells was calculated by microscopic examination of cells 
displaying blue nuclear fragmentation (Hoechst) and red 
nuclear fragmentation (PI), indicating the induction of early 
and late apoptosis. As shown in Fig. 1d, siRNA-mediated 
depletion of wild-type and mutant KRAS had an impact 
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Figure 1: Silencing oncogenic KRAS in KRAS-addicted NSCLC cells. a. Ras-GTP levels in NSCLC cells expressing mutant 
KRAS, mutant EGFR or their wild-type form were measured with a pull-down assay (PD). GTP-bound Ras, isolated from the PD and 
total cell lysate (TCL) subjected to immunoblot analysis are shown. Values represent normalized ratios of active RAS to total RAS levels, 
quantified by Image J analysis. b. NSCLC cells transiently transfected with wild-type KRAS or mutant KRAS (G12C) siRNA for 72 hrs 
were assessed for cell growth by MTS (values are representative of mean ± SEM of three independent experiments) and c. immunoblot 
analysis with the indicated antibodies. d. Cellular apoptosis was quantified by Hoechst 33342 (blue) and propidium iodide (red) double 
fluorescent chromatin staining on cell cultures 72 hrs post siRNA transfection. Representative images of two independent experiments from 
3 to 5 randomly selected microscopic fields are shown (40× magnification). Also see Supplementary Figure S1.
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on the survival of H358 cells with a respective increase 
of 8.4 ± 0.2% (wild-type) and 14.8 ± 1.0% (mutant) in the 
number of apoptotic cells relative to control. In addition, 
H23 NSCLC cells treated under similar conditions 
displayed comparable results (Fig. S1c). No significant 
apoptotic effects were observed with the other NSCLC 
cell lines after similar siRNA treatment (Fig. 1d). Taken 
together, these results indicate that although knock down 
of KRAS G12C in dependent NSCLC cells causes growth 
inhibition and a modest induction of apoptosis, this effect 
may be attenuated by the upregulation of phosphorylated 
STAT3 and hence the increase of survival signals.
EGFR/HER-dependent and EGFR/ 
HER-independent isoforms of KRAS  
mutant NSCLC
KRAS is central to multiple signaling cascades and 
has been shown to induce growth-factor independence and 
constitutively activate downstream signaling effectors in 
its oncogenic form [13]. To further investigate whether 
oncogenic KRAS activity could be influenced by 
stimulation of EGF or other HER-family related ligands, 
a panel of mutant KRAS NSCLC cells - H358 (KRASG12C; 
EGFRwt), H23 (KRASG12C; EGFRwt) , A427 (KRASG12D; 
EGFRwt) and A549 (KRASG12S; EGFRwt amplification) - were 
serum starved overnight and then stimulated with 
epidermal growth factor (EGF) or neuregulin 1β (NRG1β) 
for ten minutes. As shown in Fig. 2, acute stimulation of 
H358 cells with EGF, strongly enhanced KRAS-GTP and 
pan-RAS-GTP loading, while treatment with NRG1β, the 
ligand for HER3, mostly enhanced pan-RAS GTP levels. 
In contrast, although EGF stimulation enhanced pan-
RAS-GTP levels in H23 cells bearing the same KRASG12C 
mutation as H358 cells, it was NRG1β stimulation that 
mostly enhanced active KRAS levels (Fig. 2). These 
data indicate that H358 and H23 cells are dependent on 
extracellular growth signals from EGFR or HER2/HER3 
for enhanced KRAS GTP-loading. Examination of active 
RAS levels in the two other KRAS mutant isoforms (A427 
and A549) did not reveal an increase in either KRAS or 
pan-RAS GTP loading upon EGF stimulation (Fig. 2), 
pointing to a EGFR-independent phenotype in these cells. 
To the contrary, NRG1β stimulation even decreased their 
active KRAS and pan-RAS levels further indicating that 
A427 and A549 cells are differentially influenced by 
upstream stimulation of the EGFR/HER receptors.
Silencing the EGFR/HER in KRAS mutant 
NSCLC cells
To evaluate how KRAS-driven NSCLC cells are 
regulated by the HER receptors, we performed short 
hairpin (shRNA) -mediated knockdown of EGFR, HER2 
and HER3 on two candidate cell lines from the EGFR/
HER-dependent (H358) and EGFR/HER independent 
(A549) groups (as evaluated in Fig. 2). The cells were 
transfected with the shRNA plasmids, enriched in medium 
containing puromycin; followed by assessments of active 
KRAS-GTP and EGFR/HER levels. shRNA-mediated 
knockdown of EGFR in H358 cells potently reduced, 
by approximately five-fold, active KRAS-GTP levels 
compared to shRNA targeting the luciferase control gene, 
as well as HER2 and HER3 (Fig. 3a & 3b). For A549 
cells, treatment with the HER shRNAs did not induce 
a significant depletion in KRAS-GTP levels (Fig. 3a & 
3b). Combined knockdown of EGFR and HER2 potently 
reduced KRAS-GTP levels in H358 cells, while similar 
shRNA treatment enhanced KRAS-GTP levels in A549 
cells (Fig. S2a).
EGFR and HER3 shRNA-mediated knockdown 
in H358 cells potently reduced phosphorylated and total 
levels of EGFR compared to control (Fig. 3c & 3d). 
Importantly, combined knockdown of EGFR and 
HER2 also produced a marked decrease in levels of 
phosphorylated and total EGFR in H358 cells (Fig. S2b). 
Although a potent reduction in EGFR phosphorylation 
was observed in A549 cells after EGFR or HER3 shRNA 
treatment, a corresponding increase in total EGFR 
levels was also observed in this cell line (Fig. 3c & 3d). 
Furthermore, treatment with HER2 shRNA in A549 
increased both phosphorylated and total levels of EGFR 
(Fig. 3c & 3d), while the combination of EGFR and 
HER2 shRNA also correlated with an increase in EGFR 
expression levels (Fig. S2b). The reason behind these 
observations remain unclear, but could be linked to an 
unknown feedback mechanism between the HER receptors 
that render mutant KRAS independent of EGFR/HER 
regulation in A549 cells.
Effect of combined HER inhibition in KRAS and 
EGFR mutant NSCLC cell lines
Oncogenic KRAS and its related signaling effectors 
are thus readily activated by upstream HER stimulation 
in certain KRASG12C NSCLC cells (see above and Fig. 2). 
We subsequently investigated the effect of targeting 
oncogenic KRAS activity indirectly, by combined 
inhibition of the HER family of receptors with the EGFR 
small molecule tyrosine kinase inhibitor erlotinib, and 
with the HER2- specific monoclonal antibody pertuzumab. 
Pertuzumab prevents HER2 from dimerizing with its other 
HER partners thereby blocking signaling [20]. The same 
panel of KRAS mutant NSCLC cells (H358, H23, A427 
and A549) previously tested (Fig. 2), was compared to 
mutant EGFR NSCLC cells (H1650 and H1975) that have 
a wild-type KRAS status.
The NSCLC cells were treated for five days 
with erlotinib (100 nM), pertuzumab (25 μg/ml), their 
combination, or vehicle control and biological effects 
were examined. All of the NSCLC cell lines display 
resistance to clinical achievable doses of single-agent 
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erlotinib or pertuzumab (data not shown). As shown in 
Fig. 4a, combined treatment significantly reduced in vitro 
cellular growth of H358 cells compared to single treatment 
conditions and a more modest reduction in the growth of 
H23 and A549 cells. In contrast, combination treatment 
yielded no growth inhibition in A427 cells (Fig. 4a).
Combination treatment in H358 cells reduced EGFR 
and HER2/3 phosphorylation resulting in the suppression 
of downstream effectors: STAT3, AKT and ERK1/2 
(Fig. 4c; also see summary table - Table S1). In H23 cells, 
active levels of EGFR/HER and downstream signaling 
effectors were unaffected (Fig. 4c). In A549 cells, erlotinib 
had a paradoxical effect of stimulating the phosphorylation 
status of EGFR and HER3, while the combination with 
pertuzumab caused only some inhibition of active HER3 
levels, but not of EGFR or HER2 (Fig. 4c; Table S1). This 
further indicates that an unknown feedback mechanism 
affecting EGFR/HER2 could be active in these KRAS 
mutant cells bearing an EGFR amplified status or that 
the dose of erlotinib employed was insufficient to block 
the overexpressed EGFR protein. In the same vein, an 
increase in active levels of all three HERs was observed in 
A427 cells upon pertuzumab treatment, while combination 
treatment yielded no significant effects on active levels of 
HER and downstream effector proteins AKT and ERK1/2 
(Fig. 4c; Table S1).
The dual effect of erlotinib and pertuzumab on 
growth and EGFR/HER activity of H1650 and H1975 
EGFR mutant NSCLC cells was less evident. No 
pronounced effects were observed in comparison to single 
treatment conditions (Fig. 4b and 4d).
Combined HER inhibition promotes anti-
tumor efficacy in EGFR/HER-dependent KRAS 
mutant NSCLC
Combined erlotinib and pertuzumab treatment 
severely reduced KRAS and pan-RAS GTP loading in 
H358 cells, significantly more than either treatment alone 
(Fig. 5a; H358). Interestingly, KRAS protein expression 
was strongly upregulated in H358 cells (doublet band in 
Fig. 5a; H358) upon combined treatment. In H23 cells, 
there was also a reduction in both KRAS and pan-RAS GTP 
levels compared to single treatment conditions (Fig. 5a).
We further examined the impact of combined HER 
inhibition on the invasive capabilities of H358 and H23 
Figure 2: Effects of acute growth factor stimulation on RAS activity in mutant KRAS NSCLC cells. NSCLC cells were 
serum starved for 16 hrs and stimulated for 10 minutes with the indicated ligands. Ras-GTPlevels were measured with a pull down (PD) 
assay and total cell lysates (TCL) were subjected to immunoblot analysis with the indicated antibodies.
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cells, by culturing the cells on a type I collagen substrate 
in the presence of the inhibitors or their combination. Of 
note, H358 cells typically form colonies on top of collagen 
whereas H23 cells attach and form invasive extensions 
inside the substrate. Combining erlotinib and pertuzumab 
reduced the tendency of H358 cells to form colonies on a 
type I collagen matrix (Fig. 5b); with a six-fold reduction 
in colony size observed after combined treatment (Fig. 5c). 
The invasive growth of H23 cells was attenuated after 48 
hrs post combination treatment, as depicted by the reduced 
number of invasive extensions (Fig. 5d). Quantification 
demonstrated that combined treatment exerted a 
17.02 ± 1.2% (p < 0.01) or a four-fold decrease in the 
invasive capacity of H23 cells compared to vehicle control 
(Fig.  5e).
Finally, to evaluate the in vivo anti-tumor efficacy 
of combined erlotinib and pertuzumab treatment in 
NSCLC-derived mutant KRASG12C, we examined a 
mouse model bearing xenografts of H358 cells. Tumor 
bearing mice were randomized into individual groups 
(n = 8) and treated with either vehicle, single or sequential 
combination treatment ([erlotinib 60 mg/kg/oral; 
pertuzumab 7 mg/kg/i.p.] 3x weekly) for 17 days. As 
shown in Figures 6a, 6b and 6c, sequential combination 
treatment reduced tumor volume and tumor weight after 17 
days. In addition, a 50 ± 12.9% reduction in tumor volume 
was observed in the combination treatment group already 
within seven days of treatment (Fig. 6b). Histological 
analysis of the xenografted tissue revealed a lower amount 
of the epithelial component and higher amount of stroma 
in the combined treatment group compared to the other 
groups (Fig. 6d). This observation further demonstrates 
reduced tumor cell growth in this dual treatment cohort. 
In addition, some tumor sections from the combination 
Figure 3: Silencing EGFR/HER in mutant KRAS NSCLC cells. Cells were transfected with shRNA targeting Luciferase, 
EGFR, HER2 and HER3 and enriched with puromycin (see Materials and Methods). Ras-GTP levels were measured with a pull down 
(PD) assay and total cell lysates (TCL) were subjected to immunoblot analysis with the indicated antibodies a, c. b, d. Values of KRAS-
GTP and phosphorylated EGFR levels from the immunoblot analyses in (a, c) are shown in histograms. Values are normalized relative to 
Luciferase shRNA treatment as quantified by Image J analysis. Also see Supplementary Figure S2.
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treatment group exhibited pyknotic nuclei, suggesting the 
induction of apoptosis. This observation was not made in 
analyzed tumor sections from the other treatment groups. 
Moreover, quantification of the epithelial to stromal ratio 
confirmed that this ratio was strongly decreased in the 
combined treatment group, approximately 12 fold when 
compared to vehicle control, and approximately 5 and 6 
fold when compared to erlotinib and pertuzumab treatment 
groups respectively (Fig. 6e). Ki67 cellular proliferation 
immunostaining was also performed on the tumor sections, 
but did not display any distinct variation across the four 
groups (data not shown). The Ki67 index was low in all 
treatment groups. The mouse tumor sections were further 
analyzed for the presence of DNA fragmentation and 
late apoptosis using a TUNEL-based assay. The analysis 
revealed a modest 1.5 to 2- fold increase in TUNEL 
positive cells in the combined treatment group compared 
to the other respective groups (Fig. S3c).
To determine the status of active EGFR/HER and 
active KRAS/pan-RAS levels across all treatment groups, 
we performed both immunoblot analysis and a Raf ‘pull 
down assay’ on cell lysates extracted from crude tumor 
tissue. Comparison of active EGFR/HER levels in the 
individual treatment groups demonstrated that combined 
treatment potentiated a decrease in phosphorylated 
EGFR at activating residues (Tyr 1068 and Tyr 1173) 
as well as a corresponding decrease at the activating Tyr 
1248 residue of HER2 (Fig. S3a). Importantly, levels of 
active EGFR/HER were higher in the single treatment 
groups compared to vehicle control (Fig. S3a). As shown 
in Fig. S3b, active KRAS levels were severely reduced 
in the combination treatment group, consistent with our 
results obtained in vitro. Surprisingly, active pan-RAS 
levels remained unaffected across all groups suggesting 
that EGFR/HER inhibition is specific to the KRAS-
addicted phenotype of H358 cells.
DISCUSSION
In the current study, we investigated upstream events 
that may influence the mutant KRAS signaling pathway 
in NSCLC. We found that EGF or NRG1β stimulation can 
strongly enhance the amount of active RAS in NSCLC 
Figure 4: Effect of erlotinib and pertuzumab combination on growth and EGFR/HER signalling in KRAS and EGFR 
mutant NSCLC cells. Cells were treated with erlotinib (100 nM), pertuzumab (25 μg/ml) or their combination for five days. a, b. 
Growth inhibition was determined by the SRB in vitro toxicology assay. Data are expressed relative to control and are representative of 
mean ± SEM of two to three independent experiments c, d. Total cell lysates were subjected to immunoblot analysis with the indicated 
antibodies. Also see summary table (Table S1).
Oncotarget8www.impactjournals.com/oncotarget
Figure 5: Anti-tumor efficacy of erlotinib and pertuzumab combination in EGFR/HER-dependent KRAS mutant 
NSCLC cells. H358 and H23 NSCLC cells were treated with erlotinb (100 nM), pertuzumab (25 μg/ml) or their combination for five 
days. a. Active bound Ras-GTP levels in mutant KRAS H358 cells were measured with a pull-down (PD) assay, and total cell lysate (TCL) 
subjected to immunoblot analysis are shown. b. H358 cells were cultured for 21 days on a collagen type I gel in the presence of the indicated 
inhibitors. Colonies were fixed and stained with crystal violet and bright-field images are representative of 20× magnification (Bar, 100 μm) 
c. Quantification of colonies formed by H358 cells after inhibitor treatment. d. Phase contrast images of H23 cells cultured on a collagen 
type I gel for 48 hrs in the presence of the indicated inhibitors. Arrows indicate invasive extensions and images are representative of 40× 
magnification (Bar, 50 μM). e. Invasive index quantification of H23 cells after inhibitor treatment. Values from (c) and (e) are representative 
of mean ± SEM.
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Figure 6: Anti-tumor efficacy of sequential erlotinib/pertuzumab treatment in KRAS mutant xenografts. KRAS mutant 
H358 cells were implanted subcutaneously into nude mice until tumors reached a volume of approximately 100 mm3. Xenografts (n = 8) 
were randomized and received vehicle, 60 mg/kg erlotinib, 7 mg/kg pertuzumab or their combination three days a week for 17 days. 
a. Representative images of tumor bearing mice and resected tumors from respective treatment groups. Scale bar, 10 mm b. Change in 
tumor volume of individual treatment groups. c. Comparison of tumor weight from respective treatment groups. d. Representative H&E 
stained mouse tumor sections from respective treatment groups. Scale bar, 100 μM e. Quantification of epithelial to stromal ratio of 
H&E stained tumor sections from individual treatment groups. Values from (b), (c) and (e) are representative of mean ± SEM. Also see 
Supplementary Figure S3.
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cells harboring oncogenic KRASG12C. In accordance with 
our findings, a recent report demonstrates that oncogenic 
KRAS requires EGF stimulation for enhanced activity 
in pancreatic cancer cells: EGF induced a prolonged 
activity of oncogenic KRAS, whereas only transient 
effects are seen in cells with wild type KRAS [15]. 
Surprisingly, while EGF stimulation had no effect in 
increasing the levels of KRAS-GTP in some other 
examined mutant isoforms of KRAS, NRG1β treatment 
reduced active levels of KRAS in these cell lines. The 
explanation for this remains unclear, but this observation 
could be in accordance with previous data that indicate 
a possible tumor suppressor function of NRG1 [21]. 
Our observations disagree with previous reports which 
describe oncogenic KRAS as solely constitutively active 
and independent from upstream activation by EGFR 
or other RTKs [13, 22–25]. Although this is the case in 
some RAS mutant tumor types, including some of the 
NSCLC tested here, our work indicates that some KRAS 
mutant cancers retain sensitivity to upstream stimuli 
emanating from extracellular signaling in particular via 
the HER pathway. These data therefore indicate that 
mutant KRAS isoforms can be classified into two groups: 
(1) EGFR/HER/RTK -dependent or (2) EGFR/HER/RTK-
independent. To our knowledge, this is the first report that 
clearly delineates HER dependent or independent groups 
in the context of NSCLC-derived mutant KRAS.
We found that silencing oncogenic KRAS in EGFR/
HER-dependent NSCLC cells reduced cellular growth, 
and also induced a modest apoptotic signal. These findings 
are consistent with previous reports on pancreatic cancer 
cell models [17, 26]. While the depletion of KRAS 
expression by mutant-specific siRNA was accompanied by 
a reduction in AKT phosphorylation levels in the EGFR/
HER-dependent subset, it was also followed by robust 
activation of STAT3. These results suggest a feedback 
loop via STAT3 that re-establishes oncogenic signaling, 
compensating for the loss of AKT survival signals. 
Our results are compatible with findings of Sunaga 
et al. [27], who showed that there is a feedback loop 
involving autocrine secretion of TGFβ, and subsequent 
phosphorylation of EGFR and STAT3.
The sole silencing of oncogenic KRAS may thus 
not be an effective therapeutic strategy in KRAS-addicted 
cancers, since upstream events and feedback loops are 
likely to attenuate or annul the effects of the therapeutic 
intervention. To further determine how mutant KRAS 
is regulated by EGFR and other HER members, we 
investigated shRNA-mediated knockdown of EGFR, 
HER2 and HER3 in cell lines classified as EGFR/
HER-dependent or independent. Contrary to the current 
model of a constitutively active mutant KRAS, we found 
that knockdown of EGFR, successfully reduced active 
KRAS-GTP levels in the cell line representing the EGFR/
HER-dependent subset. Importantly, we also show that 
knockdown of the HER receptors potently suppressed 
phosphorylated and total levels of their proteins in the 
dependent subset. In contrast, while shRNA-mediated 
knockdown of EGFR/HER had no significant effects 
in reducing KRAS-GTP levels in the A549 cell line 
representing the EGFR/HER independent subset, 
knockdown of HER2 led to the robust upregulation of 
pEGFR and total EGFR in this cell line. We do not have 
a mechanistic explanation for this observation but our 
data suggest a feedback between the HER receptors that 
makes the mutant KRAS independent from EGFR/HER 
regulation.
We and others have previously shown that NSCLC 
cells carrying an oncogenic KRAS mutation exhibit 
primary resistance to anti-EGFR therapy with small 
molecule inhibitors such as erlotinib, and propose that 
these KRAS-addicted cells subvert upstream signals 
emanating from EGFR [28]. To confront these earlier 
findings with our current data, we inhibited EGFR, HER2 
and HER3 with a combination of erlotinib and pertuzumab 
leading to the suppression of in vitro growth and the 
inhibition of receptor signaling and downstream signaling 
effectors in the dependent subset. In contrast we found 
a paradoxical increase in phosphorylated EGFR levels 
after dual treatment in KRAS mutant A549 cells that 
harbor a wild-type EGFR amplification. Consistent with 
these molecular observations, we also did not observe 
a significant suppression of in vitro cellular growth in 
these cells. While amplification of the EGFR has been 
reported to predict response to EGFR TKIs [29], its 
concomitance with oncogenic KRAS seemingly acts as 
a driver of resistance. KRAS mutant A427 (EGFR/HER-
independent) cells were highly unresponsive to the drug 
combination treatment and also rather showed an increase 
in active HER receptor levels compared to vehicle control. 
These cell lines thus represent KRAS mutant NSCLC that 
are EGFR/HER independent, at least from a therapeutic 
perspective.
We confirmed the anti-tumor effects of a combined 
HER blockade, in mouse xenografts specifically affecting 
the epithelial component of the xenografts. Consistent 
with our findings, erlotinib combined with pertuzumab 
has been shown to surpass single therapy in inhibiting 
tumor activity in a NSCLC xenograft model with high 
EGFR protein expression (QG-56 cells) [30]. Moreover, 
preliminary observations from a small phase Ib clinical 
trial (n = 15) have revealed that erlotinib and pertuzumab 
combination therapy is well tolerated and could be 
suitable for further clinical testing in phase II [31]. 
Further exploration in larger cohorts should include the 
assessment of biomarkers such as KRAS mutation status 
and preferably be performed in patients that are early 
enough in their disease course and have a sufficient life 
expectancy to allow for a correct evaluation of treatment 
responses and outcome.
Possibly in line with our observations, Metro et al. 
recently found a differential clinical outcome for specific 
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KRAS oncogene substitutions when treated with single 
agent erlotinib only [32]. They concluded that although 
EGFR-TKI intervention may not be effective in the mutant 
KRAS/wild-type EGFR NSCLC cohort as a whole, it 
may still beneficial to patients harboring specific KRAS 
mutations. The clinical experiment was not ideal to test 
the efficacy of targeted therapies as this was in end-stage 
NSCLC patients with a very limited life expectancy. 
Nevertheless one of two responders was in a patient 
harboring a KRASG12C mutation in their tumor similar to 
our EGFR/HER dependent cells. The other responder was 
in a KRASG12A bearing tumor, not represented in the panel 
examined in our study.
In conclusion, our results point to the important 
role of the EGFR/HER interaction in KRAS activation 
and strongly suggest that in a subset of NSCLCs, mutant 
KRAS is not an independent and constitutive signal 
transduction molecule. A multi-targeted strategy that can 
abrogate the EGFR/HER/KRAS interaction may thus have 
a therapeutic perspective. This strategy should thus be 
explored in a clinical setting using molecular characterized 
NSCLCs and possibly in other cancer types as well.
MATERIALS AND METHODS
Cell lines and reagents
The human NSCLC cell lines H292 (CRL-1848™), 
H358 (CRL-5807™), H23 (CRL-5800™), A427 (HTB-
53™), H1650 (CRL-5883™) and H1975 (CRL-5908™) 
were obtained from the American Type Culture Collection, 
while the A549 NSCLC cell line was obtained from 
Sigma. All cell lines were genotyped by STR analysis. 
The inhibitors, erlotinib and pertuzumab were provided 
by Roche.
Western blot analysis and antibodies
To analyze tyrosine phosphorylation of the HER 
receptors, their downstream signalling targets and KRAS 
signalling effectors, NSCLC cells were seeded in clear-
bottomed 24 well plates at a density of 2 × 105. After 
24 hrs, all cells received fresh media with or without 
inhibitor or their combination and were further incubated 
for an additional 48 hrs; receiving fresh media and inhibitor 
daily. Cells were lysed in a Tris- buffer [25 mmol/L Tris-
HCL (pH 7.4), 150 mmol/L NaCl, 1% Triton-x, 5 ug/ml 
leupeptin] containing a protease and phosphatase inhibitor 
cocktail (Sigma). Lysates were cleared by centrifugation 
and protein concentration was determined by the Bradford 
protein assay kit (Bio-Rad) and equivalent amount of 
protein were loaded on an 8.5% resolving acrylamide 
gel and blotted on a polyvinylidene fluoride membrane 
(PVDF). The membrane was then subjected to an 
immunodetection procedure using the indicated antibodies: 
phospho-EGFR (Tyr 1086) phospho-HER2 (Tyr 887), 
phospho-HER3 (Tyr 1289), phosphor-STAT3 (Tyr 705), 
EGFR, HER2, HER3, ERK1/2, AKT/PKB, STAT3 from 
Cell Signaling, phospho-ERK1/2 (Tyr185/187), phospho-
AKT/PKB (Ser 473) from Invitrogen, and β-actin from 
Sigma-Aldrich. Horseradish peroxidase (HRP) - conjugated 
secondary antibodies (GE Healthcare; Cell Signalling) and 
a chemoluminescent detection kit (Perkin-Elmer) were used 
to detect the indicated proteins.
For RAS-GTP pull down assays, cells were cultured, 
collected and lysed. RAS-GTP was pulled down using 
the RAS-binding domain (RBD) of Raf-1 from the RAS 
activation kit (Millipore) according to the manufacturer’s 
instructions with modifications. An isoform-specific 
KRAS antibody and a pan-RAS antibody were used for 
protein detection by western blot.
Drug inhibition
The effect of drug treatment on cellular growth was 
assessed by the MTT based Sulforhodamine B (SRB) 
in vitro toxicology assay (Sigma). Briefly, cells were 
seeded in clear-bottomed 96-well plates at a density of 
2 × 103 cells/well in triplicates and treated after 24 hrs with 
concentrations of the indicated drugs or their combination. 
After the indicated time periods, the numbers of viable 
cells were fixed (trichloroacetic acid) and then stained 
with SRB. The wells were measured at an absorbance of 
490 nm using a 96-well microplate reader (Labsystems) 
according to the manufacturer’s instructions. All drug 
treatment conditions were compared to the vehicle control.
RNA interference
Wild-type and mutant-specific KRAS siRNA 
were synthesized (Eurogentec) according to a 
previously described sequence [17]. The following 
oligonucleotide sequences were used for KRAS, 
5′-GUUGGAGCUGGUGGCGUAG-3′ and for KRAS 
G12C, 5′-GUUGGAGCUUGUGGCGUA-3′. Briefly, cells 
were seeded in clear-bottomed 24-well or 96-well plates 
at a density of 0.7 to 1.5 × 105 cells/well (24 well plate) or 
2 to 8 × 103 cells/well (96 well plate) respectively. 24 hrs 
later, cells were transfected with 100 nmol/L of siRNA 
(or 50 nmol/L for their combinations) using Lipofectamine 
2000 (Invitrogen) according to the manufacturer’s 
instructions. Transfected cells were cultured at 37°C for 
the indicated time periods and collected and lysed for 
immunoblot analysis with the indicated antibodies or 
analyzed for cell growth by MTS analysis (Promega).
ShRNA constructs were based on the pKAR1/
Pur plasmid (Addgene plasmid # 23105); a gift 
from Randy Poon [33]. Specific shRNA constructs 
were created by cloning the following pairs of 
oligonucleotides into the BbsI and XbaI sites of pKAR1/
Pur: EGFR: 5′-GAGGAAAUAUGUACUACGA-3′, 
HER2:5′-GGACGAAUUCUGCACAAUG-3′, 
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HER3:5′GCAGUGGAUUCGAGAAGUG-3′ and Luciferase: 
5′ GCCAT TCTATCCTCTAGAGGATG 3′. The shRNA-
expressing plasmids were transfected into the NSCLC cells 
using Lipofectamine 2000 as described. After 48 hrs, 
medium was replaced with fresh medium containing 
0.5 μg/ml puromycin to enrich the transfected cells. 
Puromycin containing medium was removed after 
36 hrs and cells were grown in standard growth medium 
for 3 days. Cell lysates were collected and analyzed for 
RAS-GTP pull down and immunoblot analysis using the 
indicated antibodies.
Hoechst 3342/propidium iodide staining
The effects of wild-type or mutant (G12C) KRAS 
siRNA treatment on apoptosis and nuclear morphology 
in the NSCLC cells was assessed by Hoechst 33342 
and propidium iodide (PI) double fluorescent chromatin 
staining as described [28].
Collagen assay
The Collagen assay was performed as 
described [34]. Briefly, cells (1 × 105) were seeded on 
a collagen type I gel with or without treatment of the 
indicated inhibitors or their combination for the indicated 
time period. Collagen matrices were imaged under a 
phase-contrast light microscope and the invasive index 
was determined by manual counting of the number of 
invading cells (invasive extensions) and non-invading 
cells present in 5–10 randomly selected microscopic fields.
For the 21 day collagen assay, collagen matrices 
were fixed in 3% paraformaldehyde and stained with 
a 0.001% crystal violet solution followed by imaging 
under a light microscope with 10–15 randomly selected 
200× microscopic fields in each well. Quantification of 
colony size was performed by counting the number of 
pixels by computerized Photoshop CS6 analysis (Adobe).
Xenograft studies
Approximately 4.5 × 106 cultured H358 NSCLC 
cells were subcutaneously injected into the flank of 
female athymic Swiss nu/nu mice (6 weeks old). Tumor-
bearing mice were randomized into four experimental 
groups at 8 mice per group when the mean tumor volume 
was approximately 80 to 100 mm3. Randomized groups 
were treated with erlotinib by oral gavage at a dose of 
60 mg/kg/every 3 days in 0.5% methylcellulose (Sigma). 
Pertuzumab was administered intraperitoneally (i.p.) at a 
dose of 7 mg/kg/ every 3 days. In combination studies, 
groups of tumor-bearing mice received both erlotinib 
(60 mg/kg/ every 3 days, orally) and pertuzumab (3 mg/
every 3 days, i.p). Control animals were given both 
vehicles. Tumors were measured with vernier calipers 
and tumor volume estimated from 2-dimensional 
measurements using a prolate ellipsoid equation [Tumor 
Volume mm3 = (length × width2) × 0.5]. All studies were 
conducted after review by the Universiteit Gent Animal 
Care and Use Ethical Committee, in accordance with 
institutional guidelines.
Immunohistochemistry
Xenografted tumor tissue was excised 21 days 
post dose, fixed in 10% formalin and paraffin-embedded. 
Hematoxylin and eosin (H&E) assessment for general 
morphology was subsequently performed.
Statistical analysis
Results are representative of three independent 
experiments unless stated otherwise. Values are presented 
as the mean ± standard error of mean (SEM). The unpaired 
two tailed t-test was utilized to compare the means of two 
groups and the Chi-Square test was utilized for group 
comparison in the single cell collagen invasion model. 
Statistical significance is reported as follows: *P < 0.05, 
**P < 0.01, ***P < 0.001 and ****P < 0.0001.
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